140 related articles for article (PubMed ID: 37805393)
21. Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology.
Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B
Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38649148
[TBL] [Abstract][Full Text] [Related]
22. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.
Mete O; Gomez-Hernandez K; Kucharczyk W; Ridout R; Zadeh G; Gentili F; Ezzat S; Asa SL
Mod Pathol; 2016 Feb; 29(2):131-42. PubMed ID: 26743473
[TBL] [Abstract][Full Text] [Related]
23. Ectopic sphenoid sinus pituitary adenoma (ESSPA) with normal anterior pituitary gland: a clinicopathologic and immunophenotypic study of 32 cases with a comprehensive review of the english literature.
Thompson LD; Seethala RR; Müller S
Head Neck Pathol; 2012 Mar; 6(1):75-100. PubMed ID: 22430769
[TBL] [Abstract][Full Text] [Related]
24. The Clinicopathological Spectrum of Acromegaly.
Akirov A; Asa SL; Amer L; Shimon I; Ezzat S
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31766255
[TBL] [Abstract][Full Text] [Related]
25. Pleiomorphism plurihormonal Pit-1-positive macroadenoma with central hyperthyroidism: a rare case report and literature review.
Peng G; Guo C; Lv Y; Li D; Zhou L; Shen R; Chen Y; Zheng X; Sun Z; Zheng H; Long M
BMC Endocr Disord; 2022 Dec; 22(1):325. PubMed ID: 36539773
[TBL] [Abstract][Full Text] [Related]
26. Plurihormonal Pituitary Neuroendocrine Tumors: Clinical Relevance of Immunohistochemical Analysis.
Dumitriu-Stan RI; Burcea IF; Dobre R; Nastase VN; Ceausu RA; Raica M; Poiana C
Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38248047
[TBL] [Abstract][Full Text] [Related]
27. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
28. Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours.
Lenders NF; Chui J; Low J; Inder WJ; Earls PE; McCormack AI
Pituitary; 2022 Dec; 25(6):997-1003. PubMed ID: 36271964
[TBL] [Abstract][Full Text] [Related]
29. Plurihormonal pituitary adenomas.
Scheithauer BW; Horvath E; Kovacs K; Laws ER; Randall RV; Ryan N
Semin Diagn Pathol; 1986 Feb; 3(1):69-82. PubMed ID: 3039632
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology and biomarker profile of pituitary adenohypophysial tumors.
Mete O; Cintosun A; Pressman I; Asa SL
Mod Pathol; 2018 Jun; 31(6):900-909. PubMed ID: 29434339
[TBL] [Abstract][Full Text] [Related]
31. Plurihormonal pituitary adenoma immunoreactive for thyroid-stimulating hormone, growth hormone, follicle-stimulating hormone, and prolactin.
Luk CT; Kovacs K; Rotondo F; Horvath E; Cusimano M; Booth GL
Endocr Pract; 2012; 18(5):e121-6. PubMed ID: 22441009
[TBL] [Abstract][Full Text] [Related]
32. Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon.
Tordjman KM; Greenman Y; Ram Z; Hershkovitz D; Aizenstein O; Ariel O; Asa SL
Endocr Pathol; 2019 Mar; 30(1):74-80. PubMed ID: 30610567
[TBL] [Abstract][Full Text] [Related]
33. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
[TBL] [Abstract][Full Text] [Related]
34. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
[TBL] [Abstract][Full Text] [Related]
35. Pituitary adenomas with multiple cell lineage combinations: clinicopathological features and short-term prognosis.
Tang H; Wang X; Bie Z; Yang Z; Wang B; Li S; Liu P
J Neurosurg; 2023 Sep; 139(3):810-821. PubMed ID: 36708537
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1.
Fookeerah P; Varikatt W; Shingde M; Dexter MAJ; McLean M
Endocr Connect; 2023 Nov; 12(11):. PubMed ID: 37851558
[TBL] [Abstract][Full Text] [Related]
37. Plurihormonal (TSH-GH-prolactin Secreting) PIT-1-Positive pituitary Macroadenoma/Pituitary Neuroendocrine Tumor (PitNET) Associated with Graves' Disease: A Case Report.
Morgante C; Guaraldi F; Asioli S; Mazzatenta D; Papi G; Pontecorvi A
Endocr Metab Immune Disord Drug Targets; 2023; 23(12):1557-1561. PubMed ID: 37357515
[TBL] [Abstract][Full Text] [Related]
38. Immature PIT1-Lineage Pituitary Neuroendocrine Tumor: a 17-Year-Old Male with Pathogenic AIP Mutation.
Lu R; Pu C; Pekmeczi M; Perry A
Endocr Pathol; 2022 Sep; 33(3):414-416. PubMed ID: 35689747
[No Abstract] [Full Text] [Related]
39. Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor.
Wang X; Tang H; Bie Z; Wang Y; Yuan R; Zhang Z; Xiong Z; Yang Z; Bi Z; Wang B; Liu P
Neurosurgery; 2024 Jan; ():. PubMed ID: 38289085
[TBL] [Abstract][Full Text] [Related]
40. Transcription Factor Immunohistochemistry in the Classification of Pituitary Neuroendocrine Tumor/Adenoma: Proposal in a Limited-Resource Setting.
Sood R; Chatterjee D; Dutta P; Radotra BD
Arch Pathol Lab Med; 2024 Feb; 148(2):178-189. PubMed ID: 37074863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
